Loading...
Docoh

Aptose Biosciences (APTO)

Press releases

From Benzinga Pro
Aptose Reports Results for the Second Quarter 2022
2 Aug 22
Earnings, Press Releases
─ HM43239 Preliminary Response Rate of 43% Among R/R AML Patients with FLT3 Mutations Who Failed Prior Therapy with FLT3 inhibitors ─ ─ HM43239 Complete Remissions and Safety Across Three Dose Levels and Multiple
Aptose to Present at the Canaccord Genuity 42nd Annual Growth Conference
27 Jul 22
News, Health Care, Press Releases
SAN DIEGO and TORONTO, July 27, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral
Aptose to Report Second Quarter 2022 Financial Results and Hold Conference Call on Tuesday, August 2, 2022
19 Jul 22
Press Releases
SAN DIEGO and TORONTO, July 19, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat
Aptose Appoints Fletcher Payne as Senior Vice President, Chief Financial Officer
27 Jun 22
News, Management, Press Releases
SAN DIEGO and TORONTO, June 27, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral
Aptose Presents Highlights from Corporate Update and KOL Event
2 Jun 22
Health Care, Press Releases
HM43239 Delivers New Complete Remission at 160mg Dose in AML with Wildtype FLT3 New "G3" Formulation of Luxeptinib Demonstrates Encouraging PK Results SAN DIEGO and TORONTO, June 02, 2022 (GLOBE NEWSWIRE) -- Aptose
Aptose Biosciences Announces Results of Annual Meeting of Shareholders
31 May 22
Health Care, Press Releases
SAN DIEGO and TORONTO, May 31, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral
Aptose to Provide Program Updates at KOL Webinar on Thursday, June 2nd
25 May 22
News, Health Care, Press Releases
SAN DIEGO and TORONTO, May 25, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat